TY  - 
  - Reviews
  - O'Brien, DI,Nally, K,Kelly, RG,O'Connor, TM,Shanahan, F,O'Connell, J
  - 2005
  - October
  - Targeting the Fas/Fas ligand pathway in cancer
  - Validated
  - 1
  - Altmetric: 2 ()
  - apoprosis chemotherapy drug resistance Fas/CD95 Fas ligand/CD95L inflammation interferon (IFN)-gamma NF-KAPPA-B AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME TUMOR-INFILTRATING LYMPHOCYTES INTERFERON-GAMMA PRODUCTION APOPTOSIS-INDUCING LIGAND CONFER IMMUNE PRIVILEGE FAS-MEDIATED APOPTOSIS DRUG-INDUCED APOPTOSIS HUMAN COLON-CANCER IFN-GAMMA
  - Fas is a transmembrane receptor that can induce apoptosis after cross-linking with either agonistic antibodies or with Fas ligand (Fast). Although originally described as an important regulator of peripheral immune homeostasis, accumulating evidence suggests that the Fas/FasL system plays an important role in tumour development. In addition to its proapoptotic functions, accumulating evidence demonstrates that Fas can activate numerous nonapoptotic signalling pathways, and that activation of these pathways can result in increased tumourigenicity and metastasis. This review summarises the current understanding of the Fas/FasL system in tumorigenesis and discusses attempts to utilise the Fas/FasL system in the treatment of cancer.
  - 1031
  - 1044
  - 10.1517/14728222.9.5.1031
DA  - 2005/10
ER  - 

@review{V243942711,
   = {Reviews},
   = {O'Brien,  DI and Nally,  K and Kelly,  RG and O'Connor,  TM and Shanahan,  F and O'Connell,  J },
   = {2005},
   = {October},
   = {Targeting the Fas/Fas ligand pathway in cancer},
   = {Validated},
   = {1},
   = {Altmetric: 2 ()},
   = {apoprosis chemotherapy drug resistance Fas/CD95 Fas ligand/CD95L inflammation interferon (IFN)-gamma NF-KAPPA-B AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME TUMOR-INFILTRATING LYMPHOCYTES INTERFERON-GAMMA PRODUCTION APOPTOSIS-INDUCING LIGAND CONFER IMMUNE PRIVILEGE FAS-MEDIATED APOPTOSIS DRUG-INDUCED APOPTOSIS HUMAN COLON-CANCER IFN-GAMMA},
   = {{Fas is a transmembrane receptor that can induce apoptosis after cross-linking with either agonistic antibodies or with Fas ligand (Fast). Although originally described as an important regulator of peripheral immune homeostasis, accumulating evidence suggests that the Fas/FasL system plays an important role in tumour development. In addition to its proapoptotic functions, accumulating evidence demonstrates that Fas can activate numerous nonapoptotic signalling pathways, and that activation of these pathways can result in increased tumourigenicity and metastasis. This review summarises the current understanding of the Fas/FasL system in tumorigenesis and discusses attempts to utilise the Fas/FasL system in the treatment of cancer.}},
  pages = {1031--1044},
   = {10.1517/14728222.9.5.1031},
  source = {IRIS}
}